Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Sociedad Española de Farmacia Hospitalaria
2017
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=365962268005 https://www.redalyc.org/journal/3659/365962268005/ https://www.redalyc.org/journal/3659/365962268005/html/ https://www.redalyc.org/journal/3659/365962268005/365962268005.epub https://www.redalyc.org/journal/3659/365962268005/movil |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Adherence and safety study in patients on treatment with capecitabine Francisca Fernández-Ribeiro Rosario Olivera-Fernández Carlos Crespo-Diz Medicina Adherence Capecitabine Adverse Events Quality of life Pharmaceutical care Background: The introduction of oral antineoplastic agents in therapeutics has caused a change in the treatment strategy against cancer. The objective of this study was to analyze the adherence in patients to treatment with capecitabine, their adverse events, and the overall health status of patients, as well as the relationship of these factors with adherence.Method: An observational, prospective study at 7 months, in a cohort of patients on capecitabine treatment, including treatment initiations and continuations, regardless of diagnosis or indication. The data collected were: demographic variables (age, gender), diagnostic (breast cancer, colorectal cancer, gastric cancer, off-label), adherence (tablet count, Morisky test, Sackett test), safety (assessment of adverse events, clinical evaluation by the oncologist) and quality of life (performance status, SF-12 test). Data sources: electronic clinical records (IANUS®), dispensing program for outpatients (SILICON®) and interviews with patients.Results: There were 111 evaluable patients, with a mean age of 66.7 years (range 32-86), ECOG PS 1 in 76.6%. Adherence level: 78.4% (81.7% in the initiation subgroup vs. 72.5% in the continuation subgroup). Adverse events: skin toxicity (33.33%), asthenia (25.22%), gastrointestinal toxicity (24.32%) and neurological toxicity (24.32%), mostly G1. Health status, SF-12 test: subjective evaluation as “good” in 33.30% of cases.Conclusions: The low level of adherence in the continuation subgroup can be associated with the duration of treatment, toxicities, clinical evolution, and perception of their health status. It is necessary to conduct individualized monitoring in this group of patients in order to obtain a favorable clinical response. 2017 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962268005 https://www.redalyc.org/journal/3659/365962268005/ https://www.redalyc.org/journal/3659/365962268005/html/ https://www.redalyc.org/journal/3659/365962268005/365962268005.epub https://www.redalyc.org/journal/3659/365962268005/movil 10.7399/fh.2017.41.2.10596 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.2 Vol.41